Mapping the Emerging Threat of Staphylococcus aureus and MRSA in Western Maharashtra

Background Staphylococcus aureus is a major cause of skin, soft tissue, bone, and bloodstream infections. Methicillin-resistant S. aureus presents a significant treatment challenge due to its resistance to multiple drugs. India has some of the highest rates worldwide, but there is limited regional data from Western Maharashtra. This study looked at resistance trends, particularly focusing on vancomycin and inducible clindamycin resistance. Methods Hundred isolates were collected from various clinical samples, including pus, blood, tissue, bronchoalveolar lavage, ear discharge, diabetic ulcers, and osteomyelitis. Identification used standard culture and biochemical tests. Antimicrobial susceptibility followed guidelines through disc diffusion, and vancomycin/teicoplanin MICs and D-tests were also performed. Results & Discussion The results showed ciprofloxacin resistance at nearly 80% and erythromycin resistance above 70%. Moderate resistance was found against gentamicin and trimethoprim-sulfamethoxazole. Linezolid and vancomycin had low resistance rates, with less than 5% and less than 2% respectively, although Minnimum inhibitory concentration creep (0.75–2 µg/mL) was noted. Isolates from various intensive care units had higher rates of multidrug resistance, while surgical and obstetric wards had a significant presence of MRSA. Conclusion These findings point to an urgent need for antimicrobial management, mandatory D-testing, infection control measures, and regional monitoring. Study data shows to antimicrobial resistance in S. aureus higher to fluoroquinolone and lower to vancomycin though it can be more if compile the whole region data.